9,461 reports of this reaction
2.8% of all CLOPIDOGREL reports
#2 most reported adverse reaction
MYOCARDIAL INFARCTION is the #2 most commonly reported adverse reaction for CLOPIDOGREL, manufactured by Sanofi-Aventis U.S. LLC. There are 9,461 FDA adverse event reports linking CLOPIDOGREL to MYOCARDIAL INFARCTION. This represents approximately 2.8% of all 332,980 adverse event reports for this drug.
Patients taking CLOPIDOGREL who experience myocardial infarction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYOCARDIAL INFARCTION is a less commonly reported adverse event for CLOPIDOGREL, but still significant enough to appear in the safety profile.
In addition to myocardial infarction, the following adverse reactions have been reported for CLOPIDOGREL:
The following drugs have also been linked to myocardial infarction in FDA adverse event reports:
MYOCARDIAL INFARCTION has been reported as an adverse event in 9,461 FDA reports for CLOPIDOGREL. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYOCARDIAL INFARCTION accounts for approximately 2.8% of all adverse event reports for CLOPIDOGREL, making it one of the most commonly reported side effect.
If you experience myocardial infarction while taking CLOPIDOGREL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.